Observational studyBMC gastroenterology2021
Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis.
Observational study in BMC gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Fecal surrogate markers strongly correlate with endoscopic findings in pediatric onset inflammatory bowel disease: a retrospective study in Japan.Intestinal research · 2026Article
- Comparison of Changes in Biomarkers With Changes in Endoscopic Scores in Patients With Ulcerative Colitis: A Single-Center, Retrospective, Observational Study.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Effect of Disease Extent on Leucine-Rich α2-Glycoprotein as a Marker for Endoscopic Mucosal Healing in Patients With Ulcerative Colitis.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Applying Biomarkers in Treat-to-target Approach for IBD.Current gastroenterology reports · 2025Review
- Misinterpretation and misapplication of biomarkers in inflammatory bowel disease: how do we avoid this?Expert review of gastroenterology & hepatology · 2025Review
- Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis.Crohn's & colitis 360 · 2025Article
- Laboratory Tests in Inflammatory Bowel Disease: An Evidence-Based Approach to Daily Practice.Biomedicines · 2025Review
- Clinical features and current treatment approach to ulcerative proctitis.Translational gastroenterology and hepatology · 2025Review
- Discordance between patients' perception and endoscopic assessment of disease activity in ulcerative colitis.Therapeutic advances in gastroenterology · 2025Article
- Predictors of the efficacy of vedolizumab in patients with ulcerative colitis.Nagoya journal of medical science · 2024Observational
- Biomarkers in inflammatory bowel disease: a practical guide.Therapeutic advances in gastroenterology · 2024Review
- A novel inflammatory marker for extensive ulcerative colitis; Endocan.BMC gastroenterology · 2023Article
- Monitoring of patients with active inflammatory bowel disease.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Review
- Review
- Predictive models for endoscopic disease activity in patients with ulcerative colitis: Practical machine learning-based modeling and interpretation.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFecal biomarkers are considered to be useful surrogate markers for endoscopic activity. Given the mechanisms of fecal biomarkers, we hypothesized that the extent of ulcerative colitis (UC; pancolitis, left-sided colitis, and proctitis) could affect the usefulness of fecal biomarkers for assessing endoscopic and clinical disease activity; however, few studies have evaluated the utility of fecal biomarkers in the disease extent of UC.
methodsFecal calprotectin, a fecal immunochemical test for hemoglobin, and fecal lactoferrin were used as fecal biomarkers. UC patients, who underwent colonoscopy within 30 days of the fecal biomarker test, participated in this observational study. Clinical and endoscopic disease activity was assessed using the Lichtiger Index and Mayo endoscopic subscore (MES), respectively.
resultsA total of 162 colonoscopies were performed on 133 UC patients. A correlation analysis between each biomarker and the MES for each disease-extent subgroup showed a decreased correlation in the proctitis compared with the other groups. With the exception of proctitis, it was possible to distinguish between MES 0 and MES ≥ 1 with high area-under-the-curve values for fecal calprotectin and fecal lactoferrin. The fecal immunochemical test for hemoglobin was superior at discriminating MES 0 for proctitis.
conclusionsFor the practical application of fecal biomarkers for UC patients, it is necessary to consider disease extent before use. In particular, patients with proctitis exhibit a low correlation between stool biomarkers and endoscopic findings. The usefulness of these biomarkers for endoscopic remission is reduced, except for the fecal immunochemical test for hemoglobin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.